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Article
Fibroblast growth factor–specific modulation of
cellular response by syndecan-4
Arie Horowitz, Eugene Tkachenko, and Michael Simons
Angiogenesis Research Center and Section of Cardiology, Department of Medicine, Dartmouth Medical School, Lebanon, NH 03756

P

roteoglycans participate in growth factor interaction
with the cell surface through their heparan sulfate
chains (HS), but it is not known if they are otherwise
involved in growth factor signaling. It appears now that the
syndecan-4 core protein, a transmembrane proteoglycan
shown previously to bind phosphatidylinositol 4,5-bisphosphate (PIP2) and activate PKC, participates in mediating
the effects of fibroblast growth factor (FGF)2 on cell function.
Mutations in the cytoplasmic tail of syndecan-4 that either reduced its affinity to PIP2 (PIP2) or disrupted its
postsynaptic density 95, disk large, zona occludens-1
(PDZ)-dependent binding (PDZ) produced a FGF2-specific
dominant negative phenotype in endothelial cells as evi-

denced by the marked decline of their migration and proliferation rates and the impairment of their capacity to
form tubes. In both cases, the molecular mechanism was
determined to consist of a decrease in the syndecan-4–
dependent activation of PKC. This decrease was caused
either by inhibition of FGF2-induced syndecan-4 dephosphorylation in the case of the PDZ mutation or by
disruption of basolateral targeting of syndecan-4 and its
associated PDZ-dependent complex in the case of the
PIP2 mutation. These results suggest that PKC activation
and PDZ-mediated formation of a serine/threonine phosphatase-containing complex by syndecan-4 are downstream
events of FGF2 signaling.

Introduction
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possibility of fulfilling specific functional roles seems particularly relevant to the syndecan core proteins, all of which
share a distinct and highly conserved cytoplasmic tail. One
of the motifs common to all the syndecans is a COOH-terminal postsynaptic density 95, disk large, zona occludens-1
(PDZ)-binding motif now known to bind at least four PDZ
domain–containing partners (Grootjans et al., 1997; Cohen
et al., 1998; Hsueh et al., 1998; Ethell et al., 2000; Gao et
al., 2000). Similar to other PDZ proteins, these binding partners very likely serve as adaptors between the syndecans and
additional members of larger complexes.
Syndecan-4, the most widely spread member of the family,
differs in its sequence from the other three syndecans by
a unique phosphatidylinositol 4,5-bisphosphate (PIP2)–
binding seven-residue motif located in the middle of its
28–amino acid–long cytoplasmic tail (Lee et al., 1998;
Horowitz et al., 1999). Syndecan-4 has been implicated in
signal transduction (Volk et al., 1999) and the activation of
PKC (Oh et al., 1997b). PIP2 appears to underlie the
signaling activity of the cytoplasmic tail of syndecan-4, serving
as a binding interface (Horowitz et al., 1999), an essential cofactor for PKC activation (Oh et al., 1998), and a facilitator of
the tail’s multimerization (Oh et al., 1997a). These properties
are regulated by the phosphorylation of S183 located four
residues away from the NH2 terminus of the PIP2-binding
motif (Horowitz and Simons, 1998a). Once phosphory-
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The participation of heparan sulfate (HS)* chains in binding
numerous soluble ligands and extracellular matrix proteins
(Bernfield et al., 1999) drew increased attention once HS
presence on the cell surface was shown to be required for
fibroblast growth factor (FGF)2-dependent cell growth
(Rapraeger et al., 1991). The list of HS-binding soluble
ligands has grown significantly, culminating recently in the
finding that syndecan-1–attached HS chains promote the
tumorigenic response to Wnt-1 (Alexander et al., 2000).
The potential role of the HS-carrying core of the proteoglycans in mediating the cellular response to growth
factors received little attention, however, despite earlier
indications of their response to extracellular signals, such
as the recruitment of syndecan-4 to focal adhesions (Woods
and Couchman, 1994; Baciu and Goetinck, 1995). The
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lated, the affinity of the cytoplasmic tail for PIP2 and its capacities to oligomerize and activate PKC in the presence of PIP2
are sharply reduced (Simons and Horowitz, 2001).
Given the HS dependence of the activity of several growth
factors and the in vivo–observed increase in syndecan-4 expression during growth factor-regulated healing from injury
(Gallo et al., 1994; Nikkari et al., 1994; Li et al., 1997), we
asked whether the molecular attributes of syndecan-4 listed
above are relevant to growth factor signaling. Using FGF2 as
an HS-binding growth factor prototype, we found that disruption of either the PIP2 or PDZ-binding domains of syndecan-4 conferred a dominant negative phenotype in regard
to this growth factor but not to serum or epithelial growth
factor (EGF)- and PDGF-induced response.
Therefore, these data suggest that syndecan-4 selectively
regulates FGF2 signaling in endothelial cells.

Results
Site-directed mutations in syndecan-4 confer dominant
negative effects on FGF2 signaling in endothelial cells
We addressed the potential role of syndecan-4 in regulating
the cellular response to FGF2 by transfecting rat fat pad endothelial cells (RFPECs), which express syndecan-4 endogenously (Kojima et al., 1992), with hemagglutinin (HA)tagged wild-type (WT) (S4) syndecan-4 or with HA-tagged
syndecan-4 constructs mutated at two key sites (Fig. 1 A). In
the first construct (PIP2), the three consecutive residues
Y192KK in the cytoplasmic tail of syndecan-4 were mutated
to LQQ, a mutation that drastically reduces the PIP2 affinity
of the cytoplasmic tail and inhibits its PIP2-mediated activation of PKC (Horowitz et al., 1999). In another construct
(PDZ), the COOH-terminal residue (A202) was deleted,
thereby abolishing PDZ-dependent binding of syndecan-4
(Songyang et al., 1997). Finally, a PIP2/PDZ construct
combined the features of the other two constructs.
To measure the expression level of the introduced constructs
and the effect of exogenous construct expression on endogenous syndecan-4 levels, we immunoblotted total cell lysates
from each of the cell lines with antibodies to syndecan-4 and
HA (Fig. 1 B). The syndecan-4 immunoblot represents the
sum of endogenous and transfected syndecan-4 proteins,
whereas the HA immunoblot assesses the amount of transfected syndecan-4. The immunoblots showed on average a
twofold increase in the expression level of the exogenous constructs over the endogenous syndecan-4 protein in the transfected cell lines, excluding the PIP2 cells where the mutated
syndecan-4 variant is not recognized by the antibody against
the cytoplasmic tail used in these experiments, since the LQQ
mutation disrupts its epitope (unpublished data).
To find whether these mutations perturbed FGF2 signaling, we examined several potentially susceptible cell functions. Migration rate in response to FGF2 treatment was
measured by a wounding assay of confluent cell monolayers. The migration rates of cells expressing either PIP2 or
PDZ syndecan-4 mutants were similar to each other and
threefold lower than the migration rate of vector-transfected RFPECs (Fig. 2 A). At the same time, migration of
cells carrying the combined PIP2/PDZ mutation was not

Figure 1. Syndecan-4 mutants and their expression level in RFPECs.
(A) Schemes of syndecan-4 cytoplasmic tail constructs used in the
study. From left to right: WT cytoplasmic tail (S4, solid cylinder;
PIP2-binding domain, solid sphere; COOH-terminal A202 residue),
PIP2 (Y192KK to LQQ) mutation (void cylinder), PDZ (deletion of the
COOH-terminal A202 residue) mutation, and PIP2/PDZ (combination
of both mutations). (B) Protein levels of exogenous and endogenous
syndecan-4 in transfected cell clones. (Top) Immunoblots for total
syndecan-4 protein levels using antiserum specific to the cytoplasmic
tail of syndecan-4, and a histogram representing the densitometric
values of each band (in arbitrary units). (Bottom) As above, using
HA tag antibody. Aliquots of cell lysate containing equal masses of
total protein were immunoprecipitated from each cell group with
antiserum specific to the ectoplasmic tail of syndecan-4.
Glycosaminoglycan chains were digested before gel electrophoresis.

different from controls. In agreement with our previous
observations (Volk et al., 1999), the migration rate of
RFPECs overexpressing S4 was even higher than vectortransfected cells (relative gap closure of 0.34  0.09 versus
0.27  0.03, respectively; n  12, p  0.023). Cell growth
in response to FGF2 over a period of 3 d was measured by
proliferation assays with the same cell clones used in the migration assays. Cells expressing either the PIP2 or PDZ
mutants had 3–5-fold lower proliferation rates in comparison to vector-transfected cells, whereas cells expressing the
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PIP2/PDZ mutation had the same proliferation rate as
vector controls, a pattern similar to the results of the migration assays (Fig. 2 B). Finally, tube formation on extracellular matrix basement in response to FGF2 by cell clones expressing the PIP2 or PDZ syndecan-4 mutations, but not
the PIP2/PDZ mutation, was also markedly impaired in
comparison with the continuous and articulated tube networks formed by vector-transfected cells (Fig. 2 C) or by
S4-overexpressing RFPECs (unpublished data).
The combined results of the migration, proliferation, and
tube formation experiments indicate that both the LQQ
substitution and the A202 deletion conferred a dominant
negative phenotype on RFPECs when coexpressed with endogenous syndecan-4. This effect was FGF2 specific, since
when performed in the presence of 10% serum (Fig. 2, A
and C) or in the presence of either EGF or PDGF AB (25
ng/ml each [unpublished data]) migration and tube formation by PIP2 and PDZ cells did not differ from those of
vector-transfected cells.
PIP2 mutation impairs syndecan-4 targeting to the
basolateral region
To elucidate the mechanism of the dominant negative effect
of the mutations in the cytoplasmic tail of syndecan-4, we
compared the cellular distribution of each mutated syndecan-4 variant to that of the endogenous molecule. Staining
of untransfected RFPECs with the antibody to syndecan-4
demonstrated the presence of the proteoglycan along the cell
borders and in the perinuclear region (Fig. 3, top). S4 expressed in RFPECs assumed a similar distribution (Fig. 3,
bottom). The perinuclear location coincided with the Golgi
apparatus as shown by overlap with the staining for the
Golgi scaffold protein GM130 (Nakamura et al., 1995).
Both the PIP2 and PIP2/PDZ syndecan-4 variants
maintained their Golgi localization but were no longer
present in the basolateral region (Fig. 4, A and C, respectively). In contrast with the cellular distribution of the
PIP2 and PIP2/PDZ syndecan-4 mutants, the distribution of the PDZ mutant (Fig. 4 B) did not differ from
that of the endogenous syndecan-4, indicating that syndecan-4 is targeted to the basolateral region by its association
with PIP2 rather than with a PDZ protein.
Figure 2. Effects of syndecan-4 mutations on cell function. (A)
Migration of RFPECs as measured in “wounding” assays (inset). Cells
were starved in 0.5% FBS for 24 h, scratched, and incubated for
another 6 h either with 0.5% FBS and 20 ng/ml FGF2 (black bars) or
with 10% FBS alone (white bars). Gap size was measured immediately
before (W0) and after (W6) the 6-h incubation period (W  W0  W6).
Data shown as mean  SD (n  12  18; *p  0.05). (B) Fold
increase in cell number relative to day 0 as measured in RFPEC
proliferation assays. Cells were starved as above and then treated
with 20 ng/ml FGF2 (n  3). Cells were counted immediately before
FGF2 application and at 24, 48, and 72 h after it. Data shown as
mean  SD (n  4; *p  0.05 [, vector-transfected control cells;
, PIP2 cells; , PDZ cells; , PIP2/PDZ cells]). (C) Tube
formation assays on extracellular matrix basement (Matrigel™;
Beckton Dickinson). Cells were starved as above, then treated for
24 h either with 0.5% FBS and 20 ng/ml FGF2 or with 10% FBS alone
(insets), and imaged immediately. Each cell line was assayed in
duplicate. Note that all cell lines formed normal tube networks when
treated with 10% FBS.

718 The Journal of Cell Biology | Volume 157, Number 4, 2002

Figure 3. Cellular distribution of endogenous and
transfected syndecan-4 in RFPECs. (Top) Phase (left)
and immunofluorescence (right) images of the same
untransfected RFPECs labeled with 1:50 diluted
syndecan-4 cytoplasmic tail antiserum. Arrows
point to the Golgi apparatus, and arrowheads point
to cell junctions. Nuclear staining on the right is
due to nonspecific immunolabeling. (Bottom) Confocal
immunofluorescence images of RFPECs doubly labeled
with 1 g/ml HA antibody (Roche) and 2.5 g/ml
antibody to GM130 (Transduction Laboratories),
showing the distribution of HA-tagged WT syndecan-4
(S4, left), GM-130 Golgi marker (middle), and an overlay
of both images. Bars, 25 m. Note the distribution of
both endogenous and WT overexpressed syndecan-4
(S4) along cell junctions and in the Golgi apparatus.

To further examine the effect of the PIP2 mutation on the
surface targeting of syndecan-4, the S4, PIP2, and PIP2/
PDZ variants were transfected into RFPECs via a bicistronic
enhanced green fluorescent protein (EGFP)-expressing plasmid. Each cell group was scanned at both 488 nm, the EGFP
emission wavelength, and 580 nm, the emission wavelength
of the red pycoerythrin (R-PE) fluorophore conjugated to the
secondary antibody used to detect the HA-tagged exogenous
syndecan-4. As shown in Fig. 5 A, cells transfected by S4 (Fig.
5 A, b) had high counts at both wavelengths, whereas cells expressing the PIP2 and PIP2/PDZ mutants (Fig. 5 A, c and
d, respectively) had low counts at 580 nm similar to the vector-transfected control cells (Fig. 5 A, a). Note that though
the fraction of EGFP-expressing cells out of the total PIP2
cell population is low relative to the EGFP-expressing fractions in the other three the cell populations, the ratio between
the cell fraction expressing both EGFP and PIP2 and the
fraction expressing only EGFP (1:20) is similar to the corresponding ratio (1:25) in the PIP2/PDZ cell population,
whereas the ratio in the S4 cell population is much higher
(1:3). These results confirm the conclusion drawn from the
immunofluorescence experiments that the PIP2 syndecan-4
mutant is not present on the cell surface.
The sequestration of the PIP2-mutated syndecan-4 to the
Golgi apparatus may potentially reduce the presence of endogenous syndecan-4 on the cell surface if the two could form heterooligomers. In that case, the lower responses of the PIP2 cells
to FGF2 observed in the functional assays (Fig. 2) may result
not only from the presence of the mutated form of syndecan-4,
but more trivially, from the resulting deficit in the available
FGF-binding sites along the syndecan-4–associated HS chains.
To test this possibility, we quantified the amount of syndecan-4
present on the cell surface in vector-transfected and PIP2 cells
by fluorescence-assisted cell sorting (FACS) using an antibody
against the ectoplasmic domain of syndecan-4. Since we have
shown already (Fig. 4 A and Fig. 5 A) that the PIP2 variant of

Figure 4. The distribution of syndecan-4 mutants in RFPECs.
(A) PIP2-expressing cells doubly immunolabeled with syndecan-4
cytoplasmic tail antiserum (left) and HA antibody (middle). Note
that the distribution of the PIP2 syndecan-4 (middle) was
restricted to the Golgi, whereas native syndecan-4 (left) is
localized both to the Golgi and along cell borders as in the top
right of Fig. 3. Nuclei appear in this and in B and C due to
nonspecific binding of the syndecan-4 antiserum. (B) PDZ cells
doubly immunolabeled with syndecan-4 cytoplasmic tail antiserum
(left) and HA antibody (middle). Note that the distribution of the
PDZ syndecan-4 was similar to that of HA-tagged WT syndecan-4
in Fig. 3, bottom left. (C) PIP2/PDZ cells doubly immunolabeled
with syndecan-4 cytoplasmic tail antiserum (left) and HA
antibody (middle). Note that the distribution of the PIP2/PDZ
syndecan-4 was similar to that of PIP2 syndecan-4 in Fig. 4 A,
middle. Panels on the right are overlays of the left and middle.
Bar, 25 m.
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Figure 5. FACS® analysis of exogenous and
endogenous syndecan-4 expression levels. (A)
Distributions of pIRES2-EGFP vector-transfected
(a), HA-WT–overexpressing (b), PIP2-transfected
(c), and PIP2/PDZ-transfected cells (d) as a
function of their fluorescence intensities at 488
nm (EGFP, horizontal axis, arbitrary units [AU])
and at 580 nm (R-PE, vertical axis), corresponding
to the EGFP levels expressed either alone (a) or in
tandem with each syndecan-4 variant (b, c, and
d) and to the cell surface expression levels of the
syndecan-4 variants, respectively. The quadrants
were drawn so as to enclose near to 100% of
control nontransfected cells (unpublished data)
in the lower right quadrant. Numbers in the
corners denote the percentage of the cell population
in each quadrant. Quasi colors denote count
density (red, high; blue, low). (B) Intensity distribution
(in arbitrary units) of cells labeled with antiserum to
the syndecan-4 ectoplasmic domain followed by
anti–rabbit IgG-Alexa 594, showing the levels of
cell surface expression of endogenous syndecan-4
in vector-transfected (a) and PIP2-expressing (b)
cell lines.

syndecan-4 is not present on the cell surface, the antibody
would detect only the endogenous syndecan-4. The FACS results (Fig. 5 B) show no significant differences between the
amounts of syndecan-4 molecules present on the surface of vector-transfected and PIP2 cells.
PIP2 and PDZ mutations reduce
syndecan-4–associated activity of PKC
An established signaling role of syndecan-4 is the modulation of FGF2-stimulated PIP2-dependent PKC activity
(Oh et al., 1997b; Horowitz and Simons, 1998a). Since the

activity of this PKC isoenzyme has been linked previously to
the promotion of cell growth (Kolch et al., 1993, 1996; Cai
et al., 1997; Schonwasser et al., 1998; Lallena et al., 1999;
Besson and Yong, 2000), migration (Harrington et al.,
1997), and tube formation (Wang et al., 2002), we studied
the effect of PIP2 and PDZ mutations on PKC activity
in these cells. To this end, we assayed the activity of PKC
coimmunoprecipitated with HA-tagged syndecan-4 core
proteins from the RFPEC clones expressing S4, PIP2,
PDZ, or PIP2/PDZ syndecan-4 constructs, before and
after FGF2 stimulation.
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Figure 7. Phosphorylation levels of syndecan-4. Data shown is
means  SD (n  3) of syndecan-4 phosphorylation levels measured
as described in Materials and methods. Cells were incubated in 0.5%
FBS either without (black bars) or with (white bars) 20 ng/ml FGF2
starting 2 h before radio labeling for a total of 4 h. Note the significant
difference (*p  0.05) between the phosphorylation levels of S4
and PDZ before and after FGF2 treatment (tot, total syndecan-4
population in the cell). (Insets) Immunoblots of representative
samples from each cell group and condition.

Figure 6. Syndecan-4–associated kinase activities. (A) Relative kinase
activities of HA immunoprecipitates from RFPECs starved in 0.5% FBS
for 24 h and then incubated for another 20 min either without or with
20 ng/ml FGF2, or with 10% FBS. Data shown is mean  SD (n  3) of
the ratios between the kinase activity immunoprecipitated from FGF2or FBS-treated cells and from nontreated cells of the same type. Note
that the kinase activity of S4 cells was increased significantly by FGF2
treatment relative to other cell lines and that this relative increase was
observed only when the immunoprecipitates where assayed in the
presence of PIP2 but not when assayed in the presence of Ca2 ,
phosphatidylserine, and diolein. Note also that the PIP2-dependent
kinase activities immunoprecipitated from S4 and PIP2-expressing
cells did not significantly differ from each other when cells were
treated with FBS instead of FGF2 (black bars, S4 cells; light gray bars,
PIP2 cells; white bars, PDZ cells; dark gray bars, PIP2/PDZ cells).
(B) Effects of PKC autoinhibitor peptide (AIP, 100 nM) or of Gö6976
(10 nM) on kinase activities (mean  SD, n  3) of anti-HA immunoprecipitates from RFPECs in the presence of Ca2 , phosphatidylserine,
and diolein. Results are relative to the kinase activity of untreated
control samples (insets in A and B are representative phosphoimages of
PKC I optimal substrate peptide bands used for quantifying the kinase
activities of anti-HA precipitates).

FGF2 treatment increased syndecan-4/PIP2-dependent PKC
activity eightfold in syndecan-4–overexpressing RFPECs relative to untreated cells of the same type (Fig. 6 A). On the
other hand, syndecan-4–dependent PKC activity in cells expressing PIP2, PDZ, or PIP2/PDZ syndecan-4 constructs
was not increased by FGF2. No significant FGF2-induced relative increases in syndecan-4–associated kinase activities were observed when instead of PIP2 the assays were done in the presence of Ca2 , diacylglycerol, and phosphatidylserine. The
absolute level of the Ca2 -dependent activity of PKC is typically higher by 20% than its activity in the presence of PIP2 and

the cytoplasmic tail of syndecan-4 (Horowitz and Simons,
1998a). The fact that the Ca2 -dependent PKC activities of
all of the cell lines tested did not significantly differ from each
other (Fig. 6 A), either with or without FGF2 treatment, indicates that similar amounts of PKC were immunoprecipitated
in all cases. Similar to the functional assays described above, the
increase in the syndecan-4–associated kinase activity was specific to FGF2, since no significant differences were found between the syndecan-4–associated kinase activities in serumtreated versus untreated cells. Since the kinase activities were
measured ratiometrically for each cell line (FGF2 or serumtreated versus untreated cells), they were not affected by variations between different cell lines in the absolute amounts of syndecan-4–associated PKC.
Though the binding of PKC to the cytoplasmic tail of
syndecan-4 is well documented (Oh et al., 1997b; Horowitz
and Simons, 1998a), we verified that the measured kinase
activity in these assays was produced by a calcium-dependent PKC and not by other unidentified syndecan-4–associated kinases. Both the highly specific PKC autoinhibitor
peptide (House and Kemp, 1987) and the cPKC inhibitor
Gö6976 (Martiny-Baron et al., 1993) effectively suppressed
the syndecan-4–associated kinase activity (Fig. 6 B).
PDZ syndecan-4 is hyperphosphorylated after
FGF2 stimulation
Surprisingly, the FGF2-stimulated PKC activity in cells transfected with the PDZ mutant was similar to that seen in cells
transfected with the PIP2 mutant and much lower than in cells
transfected with the native syndecan-4 construct (Fig. 6 A).
Given that the capacity of syndecan-4 to activate PKC is
sharply reduced by the phosphorylation of S183 in its cytoplas-
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mic tail (Horowitz and Simons, 1998a), we compared the effect
of FGF2 stimulation on the phosphorylation level of the PDZ
mutant to its effect on the S4 variant. FGF2 administration
lowered the phosphorylation levels of S4 in a statistically significant manner (Fig. 7) relative to its basal level, in agreement with
previously described results (Horowitz and Simons, 1998a), but
it did not lower those of the PDZ mutant. Moreover, the
phosphorylation level of the PDZ mutant after FGF2 treatment was significantly higher than its basal level. This increase
may reflect the dependence of the phosphorylation level on a
dynamic balance between the opposing actions of a kinase and a
phosphatase. The dephosphorylation of the PDZ mutant
would be impaired if the association of syndecan-4 with the putative phosphatase was mediated by a PDZ adaptor protein.
Consequently, the activity of the kinase that phosphorylates
Ser183, which could conceivably be elevated by FGF2, would be
unopposed by the phosphatase, resulting in an effective increase
in the phosphorylation level of syndecan-4.
Since it is likely that the PDZ mutant and the endogenous syndecan-4 copolymerize, the abolishment of the binding of the putative phosphatase may affect the phosphorylation levels of both syndecan-4 variants. Since the currently
available antibodies cannot separate between the endogenous and the exogenous syndecan-4 species, we were able to
measure the effect of FGF2 on the phosphorylation level
of only the total syndecan-4 population, which was not
changed significantly (Fig. 7). This outcome could be attributed to opposing and mutually canceling changes in the
phosphorylation levels of the endogenous and PDZ syndecan-4 populations in response to FGF2, thus implying that
the expression of the PDZ mutant did not significantly affect the phosphorylation level of endogenous syndecan-4.
PIP2 mutation reduces syndecan-4 PIP2-dependent
oligomerization and activation of PKC
The capacity of syndecan-4 to activate PKC is dependent on its affinity to PIP2 and on its tendency to oligomerize in the presence of this phosphoinositide (Horowitz and Simons, 1998a). The potent suppression of PKC
activity and of several cell functions by the LQQ mutation implies that the PIP2 mutant has a dominant negative effect when expressed on a background of endogenous syndecan-4. Therefore, we investigated the effect of
mixing PIP2-mutated cytoplasmic syndecan-4 tail peptide with the WT tail peptide on the combined affinity of
the mixture to PIP2 in vitro. As little as 25% of PIP 2
peptide in the total WT/PIP 2 mixture increased the apparent KD of the mixture by three orders of magnitude

Figure 8. In vitro experiments with synthetic WT and mutated
syndecan-4 cytoplasmic tail peptides. (A) Dependence of surface
plasmon resonance-measured apparent first-order equilibrium
constants (KD) between PIP2 and PIP2/WT peptide mixtures on
PIP2 peptide fraction. Note the gradual elevation in KD value upon

increasing the PIP2 peptide fraction. (B) Column elution profiles
of WT (top) and PIP2 (bottom) cytoplasmic tail peptides with
(continuous line) and without (dashed line) PIP2. Note the formation
of high-order oligomers by the WT (arrow) but not by the PIP2
peptide in the presence of PIP2. Note also that both peptides are not
present as monomers but form smaller oligomers of similar sizes
both in the presence and absence of PIP2. (C) Dependence of the in
vitro activity of recombinant PKC on PIP2 concentration in the
absence () and the presence of 1 M WT (), PIP2 (), or PDZ ()
cytoplasmic tail peptides (mean  SD, n  3–6; *p  0.05). The
mean kinase activity measured at 1 M PIP2 with 1 M WT peptide
was used as a unitary reference value.
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Figure 9. Schematic representation of
FGF2 signal transduction mediated by
syndecan-4. FGFR, FGF2 tyrosine
kinase receptor; CS, chondroitin sulfate
side chains. See Discussion for details.

compared with that of the WT peptide alone as measured
by surface plasmon resonance (Fig. 8 A).
Since syndecan-4–PIP2 binding is thought to play a role in
the oligomerization of syndecan-4 tails (Oh et al., 1997a;
Horowitz and Simons, 1998a), we examined the oligomerization capacity of the PIP2 peptide. When resolved by column
chromatography, the PIP2 peptides did not form high-order
oligomers in the presence of PIP2 unlike the WT peptides (Fig.
8 B). However, both peptides formed smaller PIP2-independent oligomers of a size between tetramers and hexamers. The
capacity of the PIP2 peptide to form low-order oligomers in the
same manner as the WT peptide may explain the significantly
higher KD between PIP2 and the 25%:75% PIP2 to WT peptide mixture reported above, since the two peptides could form
heterooligomers of a PIP2 affinity much lower than that of WT
homooligomers due to the presence of the PIP2 peptide. The
decreased affinity of the PIP2 peptide to PIP2 and its lower tendency to oligomerize were accompanied by a large reduction in
its capacity to activate PKC in the presence of PIP2 relative to
the WT peptide (Fig. 8 C). Though the PDZ peptide is
shorter than the WT peptide only by a single residue, the
COOH-terminal alanine, the PKC activity in its presence at
2.5 M PIP2 10 M was lower in a statistically significant
manner than the corresponding activities in the presence of the
WT peptide but higher than those of the PIP2 mutant.

Discussion
We have described a novel mechanism regulating growth factor
signaling, distinctive both for its specificity to FGF2 (versus serum, EGF, and PDGF) and for the pivotal role of syndecan-4.
The main feature of this signaling pathway is activation of
PKC by the syndecan-4–PIP2 complex in response to FGF2
stimulation. This process is controlled by the phosphorylation
of S183 in the cytoplasmic tail of syndecan-4 that down-regulates
the response to FGF2 by preventing PIP2-dependent oligomerization of syndecan-4 and the subsequent activation of PKC.
Our working model of this mechanism (Fig. 9) consists of
the following steps. (a) FGF2 binding to its high affinity tyrosine kinase receptor induces the activation of a putative serine/
threonine protein phosphatase type 1/2A (PP1/2A) (Horowitz
and Simons, 1998b), which is associated with the cytoplasmic
tail of syndecan-4 through a PDZ adaptor protein. (b) The

PP1/2A dephosphorylates Ser183 in the membrane proximal domain of the syndecan-4 cytoplasmic tail, which is normally
maintained at a high basal phosphorylation level. Since the HS
chains carried by proteoglycans can reach estimated lengths of
80 nm (Kato et al., 1994), the dephosphorylation is likely to occur in a trans rather than a cis mode in regard to the syndecan-4
molecule carrying the FGF2-binding HS chain. Since syndecan-4 is a transmembrane protein, this dephosphorylation may
similarly occur in the Golgi-residing syndecan-4. (c) Dephosphorylation of syndecan-4 sharply increases its affinity to PIP2
(Horowitz and Simons, 1998a). In turn, PIP2 binding facilitates
the multimerization of syndecan-4. (d) The clustered syndecan4–PIP2 complex activates PKC, which associates with syndecan-4 through PIP2 (Horowitz et al., 1999).
The existence of this regulatory mechanism is suggested by
our observations that expression of PIP2 or PDZ syndecan-4
mutants on a background of endogenous syndecan-4 inhibits cell response to FGF2 but not to serum or the HS binding
EGF and PDGF AB in a dominant negative manner. In the
case of the PIP2 mutation, the mistargeting of the mutant
syndecan-4 leads to Golgi sequestration of its PDZ-binding
partner. The critical role of this sequestration is emphasized
by the lack of dominant negative effects of the double PIP2/
PDZ syndecan-4 mutation. In the case of the PDZ deletion, FGF2 treatment would lead to an increase in the extent
of syndecan-4 phosphorylation and consequently would decrease PKC activation due to the low affinity of phosphorylated syndecan-4 for PIP2 (Horowitz et al., 1999).
A recent study on syndecan-4 knockout mice reported that
the proliferative response of skin fibroblasts extracted from
these mice did not differ from the response of cells from WT
mice (Echtermeyer et al., 2001). The difference between this
finding and the significantly reduced proliferation rates of
cells expressing the PIP2 or PDZ syndecan-4 mutants that
we observed may stem from each of the following reasons. (a)
As explained above, the expression of these mutants interferes
with the function of endogenous syndecan-4. This active perturbation of a signaling pathway was not present in the mouse
syndecan-4/ cells. (b) Differences between cell types (fibroblasts versus endothelial cells) used in the two studies. (c) Assuming that Echtermeyer et al. (2001) used the same medium
as in their migration assays (the medium used in their proliferation assays is not described), the 2% serum present in this
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medium may have contained other growth factors that compensated for the impaired response to FGF2.
PIP2 mutation: effect on plasma membrane targeting
of syndecan-4
One interesting and unexpected finding in this study is the
fact that PIP2 binding rather than the interaction with a
PDZ protein targets syndecan-4 to the plasma membrane.
The data supporting this observation include immunofluorescence staining showing reduced expression of the PIP2
and PIP2/PDZ mutants in the basolateral region and virtual absence of syndecan-4 variants containing the PIP2
mutation from the cell surface as demonstrated by FACS.
Similarly, deletion of the PDZ motif in the syndecan-2 cytoplasmic tail did not eliminate its incorporation into the
plasma membrane (Ethell and Yamaguchi, 1999).
The Golgi apparatus is a known site of PIP2 synthesis
(Godi et al., 1999; Jones et al., 2000), and the involvement
of PIP2 in protein sorting is suggested by preliminary observations (Morrow, M.W. and P. Weidman, 2000. Mol. Biol.
Cell. 11:S280a). However, the actual targeting mechanism is
still unknown. The results of the FACS experiments (Fig. 5
A) show that the PIP2 mutation precluded not only the basolateral targeting but also the overall incorporation of syndecan-4 in the plasma membrane.
The dominant negative phenotype exhibited by the PIP2
mutant suggests that it disrupts a syndecan-4–dependent protein complex involved in mediating FGF2 signaling. Interestingly, it is the presence of the PIP2 mutant and not a mere absence of syndecan-4 from the cell that impairs cellular function.
This conclusion is supported by studies of the PIP2/PDZ
mutant that does not cause a similar dominant negative phenotype, yet it is similarly absent from the plasma membrane (Fig.
4 C), and by a recently described syndecan-4 knockout mouse
(Ishiguro et al., 2000). Instead, we propose that the dominant
negative effect of the PIP2 mutation is caused by sequestration
to the Golgi apparatus of a syndecan-4–binding PDZ protein
specifically involved in FGF2 (and not serum, EGF, or PDGF)
signaling. Assuming that FGF2 signaling requires the presence
of this syndecan-4–bound PDZ protein in the basolateral region, the PIP2 mutant may compete with endogenous syndecan-4 for binding to the PDZ protein, thus capturing a large
part of this protein population at the Golgi apparatus and interfering with its targeting to the plasma membrane and the formation of a syndecan-4–dependent complex.
PDZ binding regulates syndecan-4 phosphorylation in
response to FGF2
We have shown that the dominant negative effect of the
PDZ mutation is associated with increased phosphorylation
of the PDZ syndecan-4 mutant after FGF2 treatment. The
phosphorylation state of syndecan-4 is controlled on one hand
by a novel PKC (nPKC) and on the other by a FGF2-activated PP1/2A (Horowitz and Simons, 1998b). Since the
phosphorylation level of the PDZ mutant was significantly
higher than that of S4 after FGF2 treatment, the most likely
explanation for this observation is impaired dephosphorylation of the PDZ mutant, resulting in unopposed activity of
the nPKC. This in turn suggests that the PP1/2A involved in

syndecan-4 dephosphorylation forms a complex with syndecan-4 through a PDZ adaptor protein. In the absence of the
PDZ-binding motif of syndecan-4, and hence PDZ adaptor
binding, the phosphatase would no longer dephosphorylate
the PDZ mutant. This explanation applies both to the membrane and the Golgi-associated syndecan-4 pools, since the cytoplasmic tail of the latter would protrude into the cytoplasm
and be accessible to the phosphatase and kinase.
The hyperphosphorylated PDZ mutant has reduced tendencies to oligomerize and bind PIP2, resulting in a diminished capacity to activate PKC (Horowitz and Simons,
1998a). Moreover, its presence in the plasma membrane may
interfere with the oligomerization, PIP2 binding, and activation of PKC by dephosphorylated endogenous syndecan-4.
This loss of syndecan-4–dependent activation of PKC in response to FGF2 may then account for the dominant negative
effects of the PDZ mutation.
It should be noted that the lower activity of PKC in the
presence of the PDZ peptide compared with the WT peptide
(Fig. 8 C) leaves open the possibility that the induction of a
dominant negative phenotype by the PDZ mutation can be
caused by reduction in PKC activity, similar to the PIP2
cells. Although it is not obvious how deletion of a single
COOH-terminal residue in the cytoplasmic tail of syndecan-4
produces this effect, the deletion could conceivably affect the
conformation of the PIP2-binding motif and hence reduce its
affinity to PIP2.
FGF2 specificity of the syndecan-4 signaling pathway
Another intriguing observation in this study is the apparent
FGF2 specificity (versus serum, EGF, and PDGF) of the
syndecan-4 signaling pathway. This specificity may stem in
part from the choice of functional assays used in this study,
since both cell migration (Harrington et al., 1997) and proliferation (Schonwasser et al., 1998; Besson and Yong, 2000)
have been linked to the activation of PKC, the kinase regulated by syndecan-4. However, not all FGF2-induced signaling events may necessarily be regulated in this fashion. The
fact that, unlike FGF2, serum stimulation of cell growth and
proliferation is not affected by the PIP2and PDZ syndecan-4 mutants suggests that other growth factors present in
serum, such as EGF or PDGF AB, may stimulate cell
growth and migration independent of PKC. The lack of
increase in PIP2-dependent PKC activation after serum
stimulation (Fig. 6 A) agrees with this observation.
Though all syndecans and glypicans can carry HS chains
and may, therefore, bind FGF2, only syndecan-4 selectively
modulates FGF2 signaling (Volk et al., 1999; Simons and
Horowitz, 2001). The unique nature of the syndecan-4–
dependent amplification of FGF2 signaling is related to the
presence of its cytoplasmic tail, since the expression of chimeras consisting of either glypican-1 (Volk et al., 1999) or
syndecan-1 (unpublished data) ectoplasmic domain fused to
the transmembrane and cytoplasmic domains of syndecan-4
mimics the positive effects of intact syndecan-4 overexpression on cell proliferation and migration. These findings, together with the results of the current study, suggest that PIP2
binding and the concomitant ability to activate PKC underlie the unique capacity of syndecan-4 among the cell surface proteoglycans to regulate FGF2 signaling.
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In summary, we describe a novel signal transduction pathway
that involves selective regulation of endothelial cell migration
and proliferation by FGF2 via syndecan-4.

Materials and methods
cDNA constructs, mutagenesis, and transfection
Syndecan-4 cDNA containing an ectoplasmic HA tag (Shworak et al.,
1994) was subcloned into MSCV retroviral vector (Hawley et al., 1994)
between its EcoRI and BglII sites. Site-directed mutations were introduced into syndecan-4 cDNA by PCR-mediated oligomutagenesis
(QuikChange; Stratagene). The vector was delivered into RFPECs by either retroviral (as described in Volk et al., 1999) or liposome-mediated
transfection (LipofectAmine Plus; Invitrogen). In both cases, stably transfected cells were selected by neomycin resistance (0.4 mg/ml Geneticin;
Invitrogen). Syndecan-4 expression levels were assessed by immunoblotting cell lysates as described (Horowitz and Simons, 1998a) with 50 mU/
ml HRP-conjugated 3F10 HA antibody (Roche).
Alternatively, the HA-tagged syndecan-4 cDNA constructs were inserted between the XhoI and EcoRI restriction sites of a bicistronic mammalian expression plasmid (pIRES2-EGFP; CLONTECH Laboratories) that
coexpresses EGFP and the inserted cDNA under a single promoter. RFPECs
were stably transfected by LipofectAmine 2000 (Invitrogen) and selected
by neomycin resistance as a pooled population. To enrich each pool with
cells having high expression levels of the transfected protein, only cells in
the top 2–5% of the population as determined by two to three consecutive
sorting rounds (see below) were retained and expanded.

Cell function assays
Cells were incubated as described (Horowitz and Simons, 1998a) in M199
medium (Invitrogen) with the indicated supplements. Cell migration was
measured by “wounding” assays (Tang et al., 1997) in which cells were
grown to subconfluence in 6-well plates and then starved for 24 h in 0.5%
serum. The cell layer was scratched with a pipette tip, producing a gap
2-mm wide. The gap width was measured at marked locations from images taken by inverted microscope (TMS-F; Nikon) immediately after the
scratching and again 6 h later at the same locations. Proliferation and tube
formation assays were done as described (Volk et al., 1999). All experiments were repeated with two clones of cells stably transfected with each
syndecan-4 variant. Neomycin was withdrawn from the culture medium at
least 24 h before the cell function assays and before all other experiments
with stably transfected RFPECs to prevent artifacts caused by neomycin sequestration of PIP2 (Gabev et al., 1989).

FACS
To measure the amount of exogenous syndecan-4 present on the cell surface, cells were dissociated from plates (nonenzymatic solution; SigmaAldrich), labeled with 1 g/ml antibody to HA (Roche) followed by 10
g/ml of anti–rat IgG conjugated to R-PE (Jackson Immunologicals), and
sorted automatically (FACScan®; Beckton Dickinson). Detection of the
surface expression of both exogenous and endogenous syndecan-4 was
done similarly using a 1:50 dilution of antiserum to the ectoplasmic domain of syndecan-4 (Shworak et al., 1994) and 10 g/ml of anti–rabbit
IgG conjugated to Alexa-594 (Molecular Probes). To detect the overall
cellular expression of exogenous syndecan-4, cells were scanned at the
EGFP-emitted wavelength (488 nm).

Immunofluorescence
RFPECs were plated in chamber slides (Nunc), fixed with 2% formaldehyde in PBS (137 mM NaCl, 4.3 mM Na2HPO4 7H2O, 2.7 mM KCl, 1.4
mM KH2PO4, pH 7.3) for 10 min at room temperature, washed twice
with PBS, permeabilized with 0.1% Triton X-100/PBS for 10 min, washed
again as above, blocked with 3% BSA (Invitrogen) in PBS for 30 min, and
incubated with primary antibodies at the indicated concentrations in 1%
BSA in PBS for 3 h. The slides were washed four times as above and incubated for 1 h with 10 g/ml of the appropriate secondary antibodies
conjugated either to Alexa 488 or Alexa 594 (Molecular Probes), washed
again as before, and mounted with ProLong medium (Molecular Probes).
Slides were imaged by laser-scanning confocal microscopy (Radiance2000;
Bio-Rad Laboratories, Inc.).

Immunoprecipitation
Cells were lysed and immunoprecipitated as described (Horowitz and Simons, 1998a,b) using 80 l anti-HA affinity matrix (Roche) suspension

per 750 l cell lysate. Alternatively, endogenous or HA-tagged syndecan-4 was immunoprecipitated with 10 l cytoplasmic tail antiserum
(Shworak et al., 1994) or with 5 g HA antibody (3F10; Roche) per 750
l cell lysate, respectively, and 40 l suspension of protein G plus/protein A agarose (Oncogene). Where indicated, glycosaminoglycan chains
were digested as described (Horowitz and Simons, 1998b).

Surface plasmon resonance
Experiments were performed as described (Horowitz et al., 1999) using
28–amino acid–long (Horowitz and Simons, 1998a) syndecan-4 cytoplasmic tail peptides (Genemed Synthesis) as ligands and PIP2 (SigmaAldrich) as analyte.

Column chromatography
Synthetic syndecan-4 cytoplasmic tail peptides (1 M) either alone or
mixed with PIP2 (2 M) in 0.1 M phosphate, pH 7.4, and 20% acetonitrile
were injected (22.5 l) into a 300  6 mm silica (5 m spheres, 60 Å
pores) HPLC (Waters, 515 Pump, 2487 Absorbance Detector)-mounted
column (YMC). Elution profiles corresponding to light absorbance at 210
nm were recorded digitally (Millennium32; Waters).

Kinase assays

With recombinant PKC. These were performed either in the presence of

PIP2 or Ca2 , phosphatidylserine, and diolein as described (Horowitz and
Simons, 1998a) using recombinant PKC (120 ng/ml). Kinase activity was
quantified by phosphoimaging (Molecular Dynamics) of gel-resolved
PKC I optimal substrate peptide bands. PKC autoinhibitor peptide and
Gö6976 were purchased from Calbiochem.
With immunoprecipitated syndecan-4. Syndecan-4 complexes immunoprecipitated as described above with 5 g HA antibody per 750 l cell lysate and 40 l protein G plus/protein A agarose suspension were used for
in vitro kinase assays. After washing in 25 mM Tris-HCl (pH 7.4) buffer, the
beads were sedimented, and the buffer was removed and replaced with 30
ml kinase assay buffer containing either PIP2 or Ca2 , phosphatidylserine,
and diolein as described (Horowitz and Simons, 1998a). The assay was
stopped by adding 10 l 4 Laemmli sample buffer (final concentration
2% SDS, 10% glycerol, 0.5% -mercaptoethanol, 0.004% bromophenol
blue, 50 mM Tris-HCl, pH 6.8) and boiling for 4 min. Kinase activity was
quantified as in the recombinant PKC assays.

Measurement of syndecan-4 phosphorylation level
RFPECs in 100-mm plates were grown for 24 h in phosphate-free DME (Invitrogen) supplemented with 0.5% FBS and radiolabeled for 4 h with 0.5 mCi/
ml [32P]orthophosphoric acid (New England Nuclear). Cells were washed with
tris-buffered saline (137 mM NaCl, 25 mM Tris-HCl, pH 7.4) and scraped off
in 0.5 ml lysis buffer (150 mM NaCl, 20 mM NaF, 20 mM Na4P2O7, 5 mM
EDTA, 5 mM EGTA, 1 mM Na3VO4, 1 mM PMSF, 1% Triton X-100, 50 mM
Hepes, pH 7.4) supplemented with protease inhibitor cocktail (Complete;
Boehringer). Cell lysates were precleared by incubation with 1 g nonimmune rat IgG (Sigma-Aldrich) and 20 l protein G plus/protein A agarose bead
suspension at 4C for 1 h. After agarose bead sedimentation, the cleared samples were supplemented with 80 l of anti-HA affinity matrix bead suspension
(Roche) or with 10 l cytoplasmic tail antiserum (Shworak et al., 1994) and 40
l suspension of protein G plus/protein A agarose (Oncogene) and incubated
in rotating tubes over night at 4C. The beads were sedimented, washed three
times in heparinase digestion buffer (50 mM NaCl, 4 mM CaCl2, 20 mM TrisHCl, pH 7.4), and glycosaminoglycan chains were digested as described
(Horowitz and Simons, 1998b). The immunoprecipitated syndecan-4 core
protein was dissociated from the beads by a 10-min incubation in 40 l Laemmli sample buffer at 95C. Samples were resolved on 12% tris-glycine gels
(Bio-Rad Laboratories), and the bands corresponding to the cytoplasmic tail of
syndecan-4 were identified by immunoblotting with a peroxidase-conjugated
antibody to the HA tag (Roche). The bands were excised, and the 32P level was
measured by scintillation counter (Beckman Coulter).
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